Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
A growing, painful area is not
#ClinicalPharmacology #Pharmacokinetics #PharmacyEducation #Pharmacotherapy #MedicalEducation To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in Sun Pharma joins semaglutide race with over 60% cheaper generic #Noveltreat (for weight-loss) will cost patients between Rs 3,490 and Rs 7,400, while #Sematrinity (for type-2 diabetes) monthly cost ranges between Rs 2,960 and Rs 4,790
Neurobiol Dis 42(3):211220 Xiao Q, Zhao W, Beers DR, Yen AA, Xie W, Henkel JS, Appel SH (2007) Mutant SOD1G93A microglia are more neurotoxic relative to wild-type microglia
No patents, no profits
